Trump Admin Proposes Rule to Save Medicare $1.1B on Drugs

The Trump administration proposed a new rule on Thursday that aims to prevent hospitals from charging markups on discounted drugs intended for Medicare patients. This initiative, according to administration estimates, could result in savings of approximately $1.1 billion for consumers in the upcoming year. The proposed regulation targets the "340B drug pricing program," which allows eligible hospitals to purchase outpatient drugs at a reduced price from manufacturers. These hospitals then dispense the drugs to patients, often at a lower cost than they would otherwise pay.

The core of the proposed rule is to prohibit hospitals from charging Medicare beneficiaries more for these discounted drugs than the hospitals themselves paid. This aims to ensure that the savings from the 340B program are passed on to patients, rather than being retained by healthcare providers through inflated prices. The administration asserts that this measure is crucial for enhancing the affordability of prescription drugs for seniors and other Medicare beneficiaries.

Details of the rule indicate that it would apply to Medicare Part B drugs, which are typically administered in a physician's office or hospital outpatient setting. The Department of Health and Human Services (HHS) is responsible for overseeing the implementation of such regulations. The proposal is subject to a public comment period, during which stakeholders can provide feedback before a final rule is established. This process is standard for significant regulatory changes within federal programs.

This proposed rule comes amidst ongoing efforts by the Trump administration to address rising healthcare costs, particularly for prescription medications. Previous actions have included initiatives aimed at increasing price transparency and negotiating drug prices. The administration has consistently stated its commitment to lowering out-of-pocket expenses for patients and improving the overall efficiency of the healthcare system. The projected $1.1 billion in savings is a significant figure, highlighting the potential impact of this regulatory change on Medicare's budget and patient finances.